KDR and intrahepatic cholangiocarcinoma: Anlotinib mainly targets vascular endothelial growth factor receptor 2 (VEGFR2) [10], platelet-derived growth factor receptors β, receptor tyrosine kinase and fibroblast growth factor receptor (FGFR) [11,12,13], which has shown excellent antitumor effects on various solid tumors [14,15], such as hepatocellular carcinoma, metastatic soft-tissue sarcoma [12,16], pancreatic cancer [17], intrahepatic cholangiocarcinoma [18], colorectal carcinoma [19,20], gastric cancer [21] and thyroid cancer [22,23].